The Multiple Myeloma Channel is supported with funding from AbbVie (Platinum), Sanofi (Gold), Legend Biotech (Bronze), and through an educational grant from Alexion Pharma GmbH.
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
BSH 2022 | Latest advances in immunotherapy for multiple myeloma: targets, alloCAR-Ts & immunomodulatory drugs
Guy Pratt, MD, FRCP, FRCPath, University Hospitals Birmingham NHS Foundation Trust, Birmingham, UK, talks on promising treatment targets for chimeric antigen receptor T-cell (CAR-T) therapy and bispecific T-cell engager (BiTE) immunotherapy in multiple myeloma, including BCMA, GPRC5D, and FcRH5. Prof. Pratt also highlights advances in allogeneic CAR-T therapy and mentions iberdomide, a new promising immunomodulatory drug. With so many new agents, it is now necessary to investigate how to best use and sequence these drugs. This interview took place at the 62nd Annual Scientific Meeting of the British Society for Haematology (BSH) 2022, in Manchester, UK.
